Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlphaVax VRP adjuvant
- Development stage
- Unknown
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
AlphaVax's VRP-based adjuvant is an immunotherapy platform technology utilizing viral replicon particles (VRP) derived from an attenuated strain of the Venezuelan equine encephalitis virus (VEE). These particles are propagation-defective, single-cycle alphavirus replicon particles that contain self-replicating RNA. Designed to be co-administered with tumor antigen vaccines, the VRP adjuvant enhances immune responses by leveraging the natural tropism of VEE for lymphatic tissues and dendritic cells. The self-replicating RNA can be engineered to express cytokines or other immunomodulatory molecules to further boost the immune response. This platform facilitates the activation of both cellular (T-cell) and humoral (B-cell) immunity and has been evaluated in multiple Phase I and Phase II clinical trials, demonstrating a favorable safety profile in over 500 subjects.
- Other names
- alphavaccine adjuvantRNA particle vaccine adjuvantVRP vaccine adjuvantVRP-based adjuvantVEE replicon particle adjuvant
Beyond the preview
Go deeper on AlphaVax VRP adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlphaVax VRP adjuvant.